Bill > HR5467

This bill, known as the Patient Access to Autoimmune Treatments (PAAT) Act, amends Medicare Part D to require prescription drug plan (PDP) sponsors to include drugs used to treat autoimmune diseases, hemophilia, and Von Willebrand disease starting in 2027. The legislation prohibits these plan sponsors from requiring more than one prior authorization per year for these specific drugs, with exceptions for medications typically used for short periods, certain controlled substances (like opioids and benzodiazepines), and drugs with special risk management strategies. By mandating coverage and limiting prior authorization requirements, the bill aims to improve access to critical treatments for patients with autoimmune and blood disorders. The changes are specifically made to Section 1860D-4 of the Social Security Act, which governs Medicare prescription drug coverage, and will ensure that patients with these specific medical conditions can more easily obtain the medications they need without repeated bureaucratic hurdles.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-bill/5467/all-info